Thousands of federal lawsuits alleging harm from AbbVie’s AndroGel are on the cusp of being settled, marking the end of a long legal saga about the safety of testosterone therapy and the marketing tactics used to promote it.
An agreement has been reached between AbbVie and the plaintiffs on settlement terms, though the final settlement paperwork has yet to be executed, said Ron Johnson, an attorney for the plaintiffs.
